LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) [Rocket]

Overview

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/10/2023	DEFA14A	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/10/2023	DEF 14A	Form DEF 14A - Other definitive proxy statements:
10/05/2023	4/A	Bernards Rene (Director) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
10/05/2023	4	van der Baan Bastiaan Jeroen (President and CEO) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
10/04/2023	4	Bernards Rene (Director) has filed a Form 4 on LIXTE BIOTECHNOLOGY HOLDINGS, INC.
09/29/2023	PRE 14A	Form PRE 14A - Other preliminary proxy statements:
09/27/2023	8-K	Quarterly results

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	12.3	5.3	0.0	0.0	0.0	0.0	0.2	0.0
Revenue growth	133.7%					-100.0%		-100.0%
Cost of goods sold	3.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	9.3	4.5	0.0	0.0	0.0	0.0	0.2	0.0
Gross margin	75.5%	85.5%					100.0%
Selling, general and administrative
Research and development	2.1	1.9	0.8	0.0	0.5	0.9	2.1	1.1
General and administrative	5.1	1.3	1.7	2.1	1.3	1.3	0.8	1.3
EBIT	-6.0	-2.7	-2.5	-2.1	-1.8	-2.1	-2.6	-2.4
EBIT margin	-48.5%	-51.4%					-1323.2%
Pre-tax income	-6.7	-3.3	-2.4	-2.1	-1.8	-2.1	-2.9	-2.8
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-6.7	-3.3	-2.4	-2.1	-1.8	-2.1	-2.9	-2.8
Net margin	-54.5%	-61.8%					-1427.1%

Diluted EPS	($0.50)	($0.29)	($0.22)	($0.04)	($0.03)	($0.04)	($0.06)	($0.06)
Shares outstanding (diluted)	13.5	11.3	11.2	58.8	55.8	47.9	46.8	44.4

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.